Trailing the First Vaccines, Next Generation Turns to Variants – BloombergQuint

(Bloomberg) — The rapid rollout of vaccines from front-runners including Pfizer Inc. is forcing those trailing behind to shift their focus to fighting potentially more dangerous versions of the coronavirus and find other ways to deploy their technologies.
Imperial College London is unlikely to go ahead with a late-stage trial in the U.K. to test its experimental Covid-19 shot, now that three vaccines have been approved in the country, according to Robin Shattock, the professor leading the research….

Click here to view the original article.